2. Apoptosis Stem Cell/Wnt Neuronal Signaling Membrane Transporter/Ion Channel
  3. MDM-2/p53 Notch Calcium Channel
  4. Rhodojaponin VI

Rhodojaponin VI is an orally active diterpenoid compound found in hododendron molle G. Don
(Ericaceae) (RM). Rhodojaponin VI binds rat N-Ethylmaleimide-sensitive fusion (NSF) with a Kd of 1.03 μM. Rhodojaponin VI blocks the MDM2-Notch1 signalling pathway by reducing MDM2 and Notch1 expression. Rhodojaponin VI indirectly reduces Cav2.2 current intensity by inhibiting NSF-mediated Cav2.2 trafficking. Rhodojaponin VI alleviates glomerulonephritis progression and podocyte injury in passive heymann nephritis rats. Rhodojaponin VI also has antinociceptive effects. Rhodojaponin VI can be used for the researches of heymann nephritis and pain.

For research use only. We do not sell to patients.

Rhodojaponin VI

Rhodojaponin VI Chemical Structure

CAS No. : 37720-87-9

Size Price Stock Quantity
5 mg Get quote 2 - 3 weeks 1 - 2 Weeks 3 - 4 weeks 2 - 3 weeks
10 mg Get quote 2 - 3 weeks 1 - 2 Weeks 3 - 4 weeks 2 - 3 weeks
25 mg Get quote 2 - 3 weeks 1 - 2 Weeks 3 - 4 weeks 2 - 3 weeks
50 mg Get quote 2 - 3 weeks 1 - 2 Weeks 3 - 4 weeks 2 - 3 weeks
100 mg   Get quote  
200 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Rhodojaponin VI Related Antibodies

Top Publications Citing Use of Products

View All Calcium Channel Isoform Specific Products:

View All Isoforms
N-type calcium channel L-type calcium channel P/Q-type calcium channel T-type calcium channel Calcium Channel

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Rhodojaponin VI is an orally active diterpenoid compound found in hododendron molle G. Don
(Ericaceae) (RM). Rhodojaponin VI binds rat N-Ethylmaleimide-sensitive fusion (NSF) with a Kd of 1.03 μM. Rhodojaponin VI blocks the MDM2-Notch1 signalling pathway by reducing MDM2 and Notch1 expression. Rhodojaponin VI indirectly reduces Cav2.2 current intensity by inhibiting NSF-mediated Cav2.2 trafficking. Rhodojaponin VI alleviates glomerulonephritis progression and podocyte injury in passive heymann nephritis rats. Rhodojaponin VI also has antinociceptive effects. Rhodojaponin VI can be used for the researches of heymann nephritis and pain[1][2][3].

In Vitro

Rhodojaponin VI ( pre-treated) partially blocks the MDM2-Notch1 signalling pathway in C5b-9-induced human podocyte cells by reducing C5b-9-induced MDM2 and Notch1 expression without altering p53 or Numb levels[1].
Rhodojaponin VI (0.01-100 μM; 20 min) enhances the thermal stability of NSF in rat DRG neuron lysates[2].
Rhodojaponin VI binds NSF directly (Kd = 1.03 ± 0.65 μM)[2].
Rhodojaponin VI (30 μM; 2-30 min) does not change Cav2.2 current intensity extracellularly but decreases it intracellularly in Cav2.2-HEK cells[2].
Rhodojaponin VI (30 μM; overnight) reverses the NSF-mediated increase in surface Cav2.2 expression and Cav2.2 current density in Cav2.2-HEK cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Rhodojaponin VI Related Antibodies

Western Blot Analysis[2]

Cell Line: Cav2.2-HEK cells
Concentration: 30 μM
Incubation Time: overnight
Result: Reversed the increase in surface Cav2.2 expression induced by NSF overexpression.
In Vivo

Rhodojaponin VI (0.02 mg/kg; p.o.; daily; 4 weeks) ameliorates podocyte injury and reduces proteinuria in male Sprague-Dawley rats with passive Heymann nephritis[1].
Rhodojaponin VI (0.001-0.05 mg/kg; i.p.; single dose) alleviates neuropathic pain in chronic constriction injury rats models[2].
Rhodojaponin VI (0.04-0.2 mg/kg, i.p.) exhibits potent antinociceptive effects in HOAC-induced writhing test in mice (with a writhe inhibition rate of 88.7%)[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague-Dawley rats (male, 150–180 g, induced passive Heymann nephritis)[1]
Dosage: 0.02 mg/kg
Administration: p.o.; daily; 4 weeks (starting 1 day before passive Heymann nephritis induction)
Result: Reduced peak proteinuria and increased serum albumin levels.
Reversed decreased body weight, reduced serum triglyceride levels.
Attenuated glomerular IgG immune complex deposition.
Reduced foot process fusion and restored nephrin and WT-1 expression.
Decreased desmin expression, and decreased renal MDM2 and Notch1 protein expression without altering p53 or Numb levels.
Animal Model: Sprague-Dawley rats (adult female, chronic constriction injury model)[2]
Dosage: 0.001, 0.005, 0.01, 0.05 mg/kg
Administration: i.p.; single dose
Result: Significantly increased paw withdrawal threshold and thermal withdrawal latency.
Almost eliminated the C-component of CAPs within 30 seconds, with partial recovery after washing.
Had no effect on A-components of CAPs was observed.
Molecular Weight

386.48

Formula

C20H34O7
CAS No.
SMILES

OC1[C@@]23[C@](CC[C@@]1([H])[C@](O)(C3)C)([H])[C@@](O)([C@@]4([H])[C@]([C@@H](C2)O)(C(C)([C@H]([C@@H]4O)O)C)O)C
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Rhodojaponin VI Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Rhodojaponin VI37720-87-9MDM-2/p53NotchCalcium ChannelCa2+ channelsCa channelsCav2.2-HEKSprague-DawleyNSFNumbp53HOACCIhuman podocyte cellsMDM2PHNNotch1DRG neuron lysatesCav2.2passive Heymann nephritisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Rhodojaponin VI
Cat. No.:
HY-N12768
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.